235 related articles for article (PubMed ID: 3488027)
1. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
[TBL] [Abstract][Full Text] [Related]
2. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
3. [Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432].
Kan N; Inamoto T; Hori T; Nio Y; Tsuchitani T; Kodama H; Tobe T; Ohgaki K
Nihon Gan Chiryo Gakkai Shi; 1985 May; 20(4):784-96. PubMed ID: 3877129
[No Abstract] [Full Text] [Related]
4. Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Yamasaki S; Teramura Y; Ohgaki K; Tobe T
Biotherapy; 1989; 1(3):197-206. PubMed ID: 2642023
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
6. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
7. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
[TBL] [Abstract][Full Text] [Related]
8. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
[TBL] [Abstract][Full Text] [Related]
9. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
[TBL] [Abstract][Full Text] [Related]
10. Effect of heat treatment on tumor cells and antitumor effector cells.
Mise K; Kan N; Okino T; Nakanishi M; Satoh K; Teramura Y; Yamasaki S; Ohgaki K; Tobe T
Cancer Res; 1990 Oct; 50(19):6199-202. PubMed ID: 2400985
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy of gastric cancer].
Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771
[TBL] [Abstract][Full Text] [Related]
12. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice.
Saito M; Nanjo M; Kataoka M; Moriya Y; Sugawara Y; Yoshida T; Ishida N
Cancer Res; 1988 Aug; 48(15):4163-7. PubMed ID: 3390809
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
Hashimoto M; Takashige K; Furuyashiki M; Yoshidome K; Sano R; Kawamura Y; Ijichi S; Morioka H; Koide H; Oku N; Moriya Y; Kusumoto S; Suda Y
Int Immunopharmacol; 2008 Jan; 8(1):12-9. PubMed ID: 18068095
[TBL] [Abstract][Full Text] [Related]
15. Effect of OK-432 on the lymphnode metastasis of MCA-sarcoma cell lines: a new therapeutic approach.
Inoh A; Kodama Y; Yokoro K
Hiroshima J Med Sci; 1989 Dec; 38(4):213-9. PubMed ID: 2637250
[TBL] [Abstract][Full Text] [Related]
16. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
Evans R; Kamdar SJ; Duffy T; Edison L
J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
[TBL] [Abstract][Full Text] [Related]
17. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
18. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
Ujiie T
Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
[TBL] [Abstract][Full Text] [Related]
19. Augmentation by OK-432 of generation of culture-induced killer cells.
Ujiie T
Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion.
Hihara J; Yamaguchi Y; Minami K; Noma K; Toge T
Anticancer Res; 1999; 19(2A):1077-84. PubMed ID: 10368657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
